

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **REDESIGNATION OF DIRECTOR APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGES IN COMPOSITION OF BOARD COMMITTEES**

The board (the “**Board**”) of directors (the “**Directors**”) of Extrawell Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce the following changes and appointments with effect from 7 June 2024.

#### **REDESIGNATION OF DIRECTOR**

The Board announces that Dr. Guo Yi (“**Dr. Guo**”), an independent non-executive Director (“**INED**”) of the Company since 14 April 2023, has been redesignated from an INED to an executive Director (“**Redesignation**”) and ceased to be a member of each of the audit committee, remuneration committee and nomination committee of the Board, with effect from 7 June 2024.

Dr. Guo, aged 43, obtained a bachelor degree in science (with a major in biology) and a doctorate degree in science (with a major in genetics) from the School of Life Sciences of Fudan University in 2003 and 2011 respectively. Dr. Guo has extensive experience in the fields of genetics, health care management, investment management and development for venture in biomedicine and has been committing his time and working in investment management and project development in the fields of biomedicine, medical devices and diagnostic services since August 2015. Dr. Guo was a non-executive director (from 8 June 2011 to 26 April 2012) and an executive director (from 27 April 2012 to 13 December 2015) of United Gene High-Tech Group Limited (now known as Innovative Pharmaceutical Biotech Limited) whose shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 399). He is currently the managing partner of Shanghai Rui Jian Venture Capital Management Co., Ltd.\* (上海睿筭創業投資管理有限公司), a company established in the People’s Republic of China (“**PRC**”).

There is no service contract between Dr. Guo and the Company. Upon the Redesignation, Dr. Guo has entered into a letter of appointment with the Company as an executive Director for a term commencing from the date of Redesignation until terminated by either party by giving not less than two months' notice in advance. Dr. Guo shall also be subject to retirement by rotation and re-election at the Company's annual general meeting in accordance with the bye-laws of the Company. Dr. Guo is entitled to a monthly salary of HK\$50,000 and a year-end bonus of an amount equivalent to his one month's salary (pro-rated to his length of service should it be less than a whole year) and a director's fee in the amount of HK\$70,000 per annum, which was approved by the Board pursuant to the recommendation by the remuneration committee of the Board, with reference to his background, qualifications, experience, his roles and responsibilities within the Company and the prevailing market conditions.

As at the date of this announcement, save as disclosed above, Dr. Guo (i) does not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years immediately preceding the date of this announcement; (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong; (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company; and (iv) does not hold any other positions with the Company or any member of the Group.

Save as disclosed above, there are no other matters relating to the Redesignation of Dr. Guo that need to be brought to the attention of the shareholders of the Company and there is no other information that needs to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

## **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board announces that Dr. Zeng Li ("**Dr. Zeng**") has been appointed as an INED of the Company, and a member of each of the audit committee, remuneration committee and nomination committee of the Board, with effect from 7 June 2024.

Dr. Zeng, aged 46, obtained a bachelor degree of Science in Microbiology and a doctorate degree of Science in Genetics from the School of Life Sciences of Fudan University in 2000 and 2005 respectively. Dr. Zeng has been registered as a non-practising member of the Shanghai Institute of Certified Public Accountants since 2009. Dr. Zeng has served several companies in the PRC at senior positions and has extensive experience in operation management and investment in the fields of biotech, medical devices and healthcare. Dr. Zeng is currently the chief operating officer of Cytocares (Shanghai) Inc.

There is no service contract between Dr. Zeng and the Company. Dr. Zeng has entered into a letter of appointment with the Company as an INED with no fixed term. Pursuant to the letter of appointment and the bye-laws of the Company, Dr. Zeng will hold office until the first annual general meeting of the Company after his appointment but will then be eligible for re-election at that annual general meeting and thereafter he shall be subject to retirement by rotation and re-election at the Company's

annual general meeting in accordance with the bye-laws of the Company. Dr. Zeng is entitled to a director's fee in the amount of HK\$70,000 per annum, which was approved by the Board pursuant to the recommendation by the remuneration committee of the Board, with reference to his background, qualifications, experience, his roles and responsibilities within the Company and the prevailing market conditions.

As at the date of this announcement, Dr. Zeng (i) does not hold any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years immediately preceding the date of this announcement; (ii) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong; (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not hold any other positions with the Company or any member of the Group.

Dr. Zeng has confirmed that (a) he meets the independence factors as set out in Rule 3.13(1) to (8) of the Listing Rules; (b) he did not and does not have any past or present financial or other interest in the business of the Group or did not and does not have any connection with any core connected person (as such term is defined in the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there are no other matters relating to the appointment of Dr. Zeng that need to be brought to the attention of the shareholders of the Company and there is no other information that needs to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome Dr. Zeng for joining the Board.

## **CHANGES IN COMPOSITION OF BOARD COMMITTEES**

With effect from 7 June 2024, Dr. Guo has ceased to be a member of each of the audit committee, remuneration committee and nomination committee of the Board and Dr. Zeng has been appointed a member of each of the audit committee, remuneration committee and nomination committee of the Board.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Chairman*

Hong Kong, 7 June 2024

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.*

\* *For identification purpose only*